AP418A - A process for preparing useful intermediates in the synthesis of substituted imidazole compounds. - Google Patents
A process for preparing useful intermediates in the synthesis of substituted imidazole compounds. Download PDFInfo
- Publication number
- AP418A AP418A APAP/P/1993/000565A AP9300565A AP418A AP 418 A AP418 A AP 418A AP 9300565 A AP9300565 A AP 9300565A AP 418 A AP418 A AP 418A
- Authority
- AP
- ARIPO
- Prior art keywords
- compound
- phenyl
- cgalkyl
- substituted
- unsubstituted
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title description 9
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 238000003786 synthesis reaction Methods 0.000 title description 4
- 150000002460 imidazoles Chemical class 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- -1 A-CO2R6 Chemical group 0.000 claims description 9
- 239000004305 biphenyl Substances 0.000 claims description 8
- 235000010290 biphenyl Nutrition 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 229910006069 SO3H Inorganic materials 0.000 claims description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- ISPFOTKDTUJUDE-UHFFFAOYSA-N ethyl 4-[(2-butyl-5-formylimidazol-1-yl)methyl]benzoate Chemical compound CCCCC1=NC=C(C=O)N1CC1=CC=C(C(=O)OCC)C=C1 ISPFOTKDTUJUDE-UHFFFAOYSA-N 0.000 claims 1
- NBKPQAOGTANTFK-UHFFFAOYSA-N ethyl 4-[(2-butyl-5-formylimidazol-1-yl)methyl]naphthalene-1-carboxylate Chemical compound CCCCC1=NC=C(C=O)N1CC1=CC=C(C(=O)OCC)C2=CC=CC=C12 NBKPQAOGTANTFK-UHFFFAOYSA-N 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- UCDIXJKWUCLMJK-UHFFFAOYSA-N 2-bromo-3-propan-2-yloxyprop-2-enal Chemical compound CC(C)OC=C(Br)C=O UCDIXJKWUCLMJK-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- RZUOYFGIQVKGKC-UHFFFAOYSA-N 4-[(1-aminopentylideneamino)methyl]benzoic acid Chemical compound CCCCC(=N)NCC1=CC=C(C(O)=O)C=C1 RZUOYFGIQVKGKC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- UAIVSGKSLHIONB-UHFFFAOYSA-N 1-methoxypentylideneazanium;chloride Chemical compound Cl.CCCCC(=N)OC UAIVSGKSLHIONB-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- SURMYNZXHKLDFO-UHFFFAOYSA-N 2-bromopropanedial Chemical compound O=CC(Br)C=O SURMYNZXHKLDFO-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- ZOMATQMEHRJKLO-UHFFFAOYSA-N 1h-imidazol-2-ylmethanol Chemical class OCC1=NC=CN1 ZOMATQMEHRJKLO-UHFFFAOYSA-N 0.000 description 1
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical class O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 1
- RDUCEKLOHBLLEV-UHFFFAOYSA-N 4-[(1-aminopentylideneamino)methyl]naphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(CNC(=N)CCCC)=CC=C(C(O)=O)C2=C1 RDUCEKLOHBLLEV-UHFFFAOYSA-N 0.000 description 1
- QLMGJDCOKQGJKF-UHFFFAOYSA-N 4-[(2-butyl-5-formylimidazol-1-yl)methyl]benzoic acid Chemical compound CCCCC1=NC=C(C=O)N1CC1=CC=C(C(O)=O)C=C1 QLMGJDCOKQGJKF-UHFFFAOYSA-N 0.000 description 1
- QWVFYZAYKGIEFP-UHFFFAOYSA-N 4-[(2-butyl-5-formylimidazol-1-yl)methyl]naphthalene-1-carboxylic acid Chemical compound CCCCC1=NC=C(C=O)N1CC1=CC=C(C(O)=O)C2=CC=CC=C12 QWVFYZAYKGIEFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100493710 Caenorhabditis elegans bath-40 gene Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 238000010934 O-alkylation reaction Methods 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical compound CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- RCTFHBWTYQOVGJ-UHFFFAOYSA-N chloroform;dichloromethane Chemical compound ClCCl.ClC(Cl)Cl RCTFHBWTYQOVGJ-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- MSQGUKKNARWCBF-UHFFFAOYSA-N ethyl 4-[(1-aminopentylideneamino)methyl]benzoate Chemical compound CCCCC(=N)NCC1=CC=C(C(=O)OCC)C=C1 MSQGUKKNARWCBF-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- DIFSGQKADHEBAI-UHFFFAOYSA-N methyl pentanimidate Chemical compound CCCCC(=N)OC DIFSGQKADHEBAI-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
A process for the preparation of a compound of formula
Description
PROCESS
FIELD OF THE INVENTION
The present invention relates to a process for preparing useful intermediates in the synthesis of substituted imidazole compounds. Such compounds are described in EP Application No. 90 306 204.0 as being angiotensin II receptor antagonists useful in the treatment of hypertension, congestive heart failure, renal failure, and glaucoma.
BACKGROUND OF THE INVENTION
EP Application No. 90 306 204.0 describes a process for the preparation of imidazole intermediates which comprises a high pressure liquid ammonia condensation of an alkyl alkylimidate with dihydroxyacetone to give 2-alkyl-515 hydroxymethylimidazoles. Subsequent N-alkylarylation and oxidation yields 1alkylaryl-2-alkyl-5-formylimidazoles. Although this process produces the key imidazole intermediates necessary for preparing the angiotensin Π receptor antagonizing imidazoles described therein, the high pressure step limits the quantity of compound that can be produced using this method. Therefore, there is a need for an alternate method for the preparation of the imidazole intermediates on a commercial scale.
A further challenge in developing an alternate process is the fact that the regiospecific synthesis of N-substituted imidazoles is not a straight forward operation. Few syntheses exist which result in the exclusive formation of 1,2,525 substitution on the imidazole ring.
It has now been found that the substituted 5-formylimidazole intermediates can be prepared by reacting a 2-halo-2-propenal-3-alkyl ether,-3-alkyl thioether, or -3-amine with a N-(l-iminoalkyl)aminoalkylaryl compound to produce said intermediates efficiently in high yield and high purity. The efficiency of the process and the quality and yields of the imidazole intermediates are particularly important when preparing compounds on a large scale for therapeutic use.
DESCRIPTION OF THE INVENTION
The present invention provides a process for the preparation of a compound of formula (I):
BAD ORIGINAL ft
AP 0 0 0 4 18
-2(CH2)n-R
R
CHO (I) wherein:
Rl is hydrogen, phenyl, biphenyl, or naphthyl, with each group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, I, CpC^alkyl, nitro, A-CO2RA tetrazoI-5-yI, CpC^alkyl, SO2NHR6, NHSO2R6, SO3H, CONR6R6, CN, SO2Ci-C6alkoxy, hydroxy, SCpCgalkyl, NHSO2R6, PO(OR6)2, NR6R6, NR6COH, NR^COCj-Cgalkyl, NR6CON(R6)2, NR6C0W, W, SO2W;
R^ is hydrogen, C2-CjQalkyl, C3-C^Qalkenyl, C3-CiQalkynyl, C3C^cycloalkyl, or (CH2)o_8Phenyl unsubstituted or substituted by one to three substituents selected from CpCgalkyl, nitro, Cl, Br, F, I, hydroxy, Ci-C^alkoxy, NR6r6, CO2R6, CN, CONR6R6, w, tetrazol-5-yl, NR^OCpC^lkyl,
NR6C0W, SCj-C^alkyl, SO2W, or SO2Ci-C6alkyl;
Wis CqF2q+i> wherein q is 1-3;
A is -(CH2)n-» -CH=CH-, -O(CR4R5)m-, or -S(CR4R5)m-;
each R4, R^ independently is hydrogen, Ci.Cgalkyl (unsubstituted or substituted by phenyl, biphenyl, naphthyl or C3-C6cycloalkyl), phenyl, biphenyl, or naphthyl (each of which is unsubstituted or substituted by one to three substituents selected from Cl, Br, I, F, Cj-C^alkyl, (C}-C5alkenyl)CH2,(Ci-C5alkynyl)CH2, CpCgalkoxy, CpC^, alkyl thio, NO2, CF3, CCbR^, or OH), C3-C6cycloalkyl, or phenyl(CpC2alkyl) unsubstituted or substituted by phenyl;
each R^ independently is hydrogen, Cj-Cgalkyl, or (CH2)nphenyl; each n independently is 0-4; and each m independently is 1-4;
or a pharmaceutically acceptable salt thereof, which comprises reacting a compound of formula (II):
r —C—NH
II
NH (Π)
BAD ORIGINAL
AP 0 0 0 4 1 8
-3wherein:
Rl, and n are as defined above for formula (I), with a compound of formula (III):
CHO (III) wherein:
X is Cl, Br, F, or I; and
Y is -OR^, -SR^, or -N(R^)2, wherein R^ is Cj-C^alkyl, under basic conditions and in solvent and, thereafter, optionally forming a pharmaceutically acceptable salt.
Preferably, the process can be used to prepare compounds of formula (I) in which:
R1 is phenyl, biphenyl, or naphthyl, with each group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, CF3, CpCgalkyl, nitro, CO2R6, OCR4r5cO2R6, tetrazol-5-yl, CpCgalkoxy, hydroxy, CN, or SO2NHR6;
n is 1 or 2; and
R^ is C2*Cgalkyl.
It should be noted that, as used herein, the terms alkyl, alkenyl, alkoxy and alkynyl mean carbon chains which are branched or unbranched with the length of the chain determined by the descriptor preceding the term. Also, the term alkylaryl means -(CH2)nR1 wherein Rl and n are as defined for formula (I) compounds.
In particular, the process can be used to prepare compounds of formula (I) in which Rl is phenyl or naphthyl substituted by CO2R6, preferably CO2H, n is 1, and R^ is C2-Cgalkyl, preferably n-butyl. Most particularly, the process can be used to prepare 4-[(2-n-butyl-5-formyl-lH-imidazol-l-yl)methyl]benzoic acid and 4-[(2-n-butyl-5-formyl-lH-imidazol-l-yl)methyl]naphthoic acid.
Suitably, the reaction is carried out on compounds of formula (II) in which Rl, R^, and n are as required in the desired formula (I) product. Preferably, the process is conducted with formula (II) compounds in which Rl is phenyl or naphthyl substituted by CO2R6, preferably CO2H, n is 1, and R^ is C2-Cgalkyl, preferably n-butyl.
AP Ο Ο Ο 4 1 8
Suitably, the reaction is carried out on compounds of formula (ΠΙ) in which X is Cl, Br, F, or I, preferably Br, and Y is -O-CpCgalkyl, preferably iso-propyloxy.
Preferably, the reaction is carried out by reacting a 2-haIo-2-propenal-3alkyl ether, such as 2-bromo-3-(l-methylethoxy)-2-propenal, with a N-(liminoalkyl)aminoalkylaryl compound, such as N-(l-iminopentyl)-4(aminomethyl)benzoic acid or N-(l-iminopentyl)-4-(aminomethyl)naphthoic acid, in the presence of base, such as an inorganic base, for example, sodium or potassium carbonate, or sodium or potassium hydroxide, preferably potassium carbonate, in solvent, such as water/organic solvent mixture, for example, water and tetrahydrofuran, water and acetonitrile, or water and chloroform containing 1,
4, 7, 10, 13, 16-hexaoxacyclooctadecane (18-Crown-6), preferably water and tetrahydrofuran. Suitably, the reaction is carried out at a temperature of between about 10°C and about 80°C, preferably between about 25°C and about 65°C.
Alternately, the reaction is carried out in the presence of an organic base and in an organic solvent. For example, a 2-halo-2-propenal-3-alkyl ether, such as 2bromo-3-(l-methylethoxy)-2-propenal, is reacted with a N-(liminoalkyl)aminoalkylaryl compound, such as ethyl N-(l-iminopentyl)-4(aminomethyl)benzoate or ethyl N-(l-iminopentyl-4-(aminomethyl)naphthoate, in the presence of an organic base, for example, triethylamine, diisopropylethylamine, or dimethylaminopyridine, preferably triethylamine, in an organic solvent, such as chlorinated hydrocarbons, for example, chloroform dichloromethane, or 1,2dichloroethane, preferably chloroform. Suitably, the reaction is carried out at a temperature of between about 10°C and about 80°C, preferably between about 25°C and about 65°C.
Alternately, the reaction is carried out using the N-(l-iminoalkyl)aminoalkylaryl compounds of formula (Π) as the base. For example, a 2-halo-2propenal-3-alkyl ether, such as 2-bromo-3-(l-methylethoxy)-2-propenal, is reacted with a N-(l-iminoalkyl)aminoalkylaryl compound, such as ethyl N-(liminopentyl)-4-(aminomethyl)benzoate or ethyl N-(l-iminopenty 1)-4(aminomethyl)naphthoate, in the presence of a catalytic amount of acetic acid, in an organic solvent, such as chlorinated hydrocarbons, for example, chloroform, dichloromethane, or 1,2-dichloroethane, preferably chloroform. Suitably, the reaction is carried out at a temperature of between about 10°C to about 80°C, preferably between about 25°C and about 65°C.
AP 0 0 0 4 1 8
-5The starting N-(l-iminoalkyl)aminoalkylaryl compounds of formula (II) are prepared by reacting an alkyl alkylimidate, R2c(=NH)-O-Ci-C^alkyl, for example, methyl valerimidate, with an aminoalkylaryl compound, such as 4(aminomethyl)benzoic acid.
The starting 2-halo-2-propenal alkyl ether compounds of formula (III) are prepared by halogenation and deprotection of malonaldehyde bisdialkyl acetal, followed by O-alkylation of the 2-halo-malonaldehyde intermediate.
The invention is illustrated by the following example. The example is not intended to limit the scope of this invention as defined hereinabove and as claimed hereinbelow.
Example 1
Preparation of 4-i(2-n-Butyl-5-formyl-lH-imidazol-l-yl)methyHbenzoic Acid
i. Preparation of methyl valerimidate hydrochloride
A 10 gallon, glass-lined fixed reactor was charged with 7.0 kg (84.6 mol) of valeronitrile and 2.96 kg (92.2 mol, 1.1 eq) of methanol. The solution was stirred with cooling to about 5°C under an atmosphere of nitrogen. A flow of hydrogen chloride gas from a gas cylinder was bubbled into the solution below the surface of the mixture at a rate such that the reaction temperature did not exceed 15°C. After about one hour, 3.67 kg (101 mol, 1.19 eq) of hydrogen chloride had been disbursed from the gas cylinder and addition was stopped. Stirring was continued for an additional 18 h at 0°C. Tert-butyl methyl ether (9.7 kg) was added to the suspension and stirring was continued for 3 h at 0°C. The slurry was then centrifuged under an atmosphere of nitrogen. After drying overnight under nitrogen and for several hours under reduced pressure at ambient temperature the product weighed 9.66 kg (76% yield uncorrected for purity) and had a mp of 91-92°C. The crude product was hygroscopic and was stored in sealed bottles under nitrogen at -5°C.
ii. Preparation of N-(l-iminopentyl)-4-(aminomethyl)benzoic acid
A 22 L, three-necked round bottom flask equipped with an air-powered mechanical stirer was placed under a nitrogen atmosphere. The vessel was charged with methyl valerimidate hydrochloride (2.5 kg, 16 mol) and dimethylformamide (9.2 L). A thermometer was attached and the suspension cooled to 0-15°C with a cooling bath. Triethylamine (2.3 L) was added to the reaction at such a rate so that the internal temperature did not exceed 25°C. The cooling was stopped and the
BAD ORIGINAL $
AP Ο Ο Ο 4 1 8
-6reaction was allowed to stir 1 hour. The reaction mixture was vacuum filtered using a Buchner funnel and a carboy (20 L). The filter cake was washed with additional dimethylformamide (1.0 L) and force-air dried for 15 min. The combined filtrates were saved. Another clean 22 L, three-necked round bottom flask equipped as above was placed under nitrogen. The vessel was charged with the combined filtrates from above followed by triethylamine (1.6 L) and 4-(aminomethyl)benzoic acid (1.7 kg, 11.5 mol). The thermometer was attached and the suspension was heated to an internal temperature of 65°C with a heating mantle and a temperature controller. The heating was continued for 20 hours. The reaction was cooled to ambient temperature and filtered to yield 2.5 kg of product; 92% uncorrected yield.
iii. Preparation of 2-bromo-malonaldehyde
A 12 L, three-necked round bottom flask was equipped with an air-powered mechanical stirrer with shaft, paddle, adapter, and thermometer was charged with
2.75 L of water and 110 mL of 12 N hydrochloric acid (1.32 mol). The addition funnel was charged with 2.5 kg of malonaldehyde bis(dimethyl acetal) (15.24 mol) which was then added to the stirred aqueous mixture in one portion. Stirring was continued for 30 min and a clear solution resulted. The reaction mixture was then cooled to 5°C using an ice-water bath. AIL addition funnel was charged with 790 mL of bromine (15.34 mol) and added to the reaction mixture at a rate such that the temperature did not exceed 25°C (approximately 30 min). The cooling bath was removed and the reaction mixture was allowed to stir at ambient temperature 1 hour. The reaction mixture is colorless to slightly yellow at this point. The solution was transferred to a 10 L round bottom flask and concentrated on the rotary evaporator at aspirator pressure (water bath 40°C) to approximately one-half the original volume. The reaction suspension was removed from the rotary evaporator and cooled at 10°C for 18 hour. Using a benchtop Buchner funnel and carboy (20 L), the resultant slurry was vacuum filtered. The solid was washed with 50% aqueous methanol (0.50 L) and force-air dried 2 hours. The mother liquor was returned to the 10 L round bottom flask and concentrated to approximately one-half its original volume. The flask was removed from the rotary evaporator and cooled (10°C) for 18 hours where additional solid emerged (331 g). The combined dried product was transferred to glass jars for storage to avoid contact with metal and was stored under refrigeration. This material was used as obtained; (2.0 kg, 86% uncorrected yield).
BAD ORIGINAL c
APO 0 0 4 1 8
-710 c
O c
O c
iv. Preparation of 2-bromo-3-(l-methylethoxy)-2-propenal
With moderate agitation, a 20 gallon reactor system was charged with cyclohexane (29.12 L), 2-bromo-malonaldehyde (2.33 kg), p-toluenesulfonic acid monohydrate 43.94 g, and 2-propanol (4.65 L). The contents of the reactor were heated to allow for the removal of distillate under atmospheric pressure (jacket temp. 95°C and process temp, at 66.4°C). A total of 16 L of distillate was removed from the reaction via the cooling tower. This represents approximately 47% of the total volume of cyclohexane/2-propanol (33.77 L) being removed from the reactor. The reaction solution was cooled to near ambient temperature and transferred to a 10 gallon reactor system at 40°C. An additional 6 L of distillate was removed under vacuum (~64 torr, jacket temp. 62°C, and reaction temp. 25°C). The mobile dark orange oil was drained from the vessel and transferred to a rotary evaporator receiver flask and further concentrated under house vacuum at ~30°C using a rotary evaporator. About 0.2 L more of solvent was removed. Total product obtained was 3.072 kg (16 mol, 103% yield). The product was used as obtained in the next step. This material is unstable and must be kept in a freezer (< -5°C, under nitrogen).
The shelve-life is about 2 weeks.
v. Preparation of 4-r(2-butyl-5-formyl-lH-imidazol-lyDmethyllbenzoic acid
A 10 gallon, glass-lined fixed reactor was charged sequentially under nitrogen gas with tetrahydrofuran (17.96 L), N-(l-iminopentyl)-4(aminomethyl)benzoic acid (2.2 kg, 9.4 mol), potassium carbonate (1.94 kg), and water (2.19 L). The suspension was then stirred. 2-bromo-3-(l-methylethoxy)-2propenal (1.99 kg, 10.3 mol) was added in one portion using ~0.3 L tetrahydrofuran as rinse. The stirred mixture was heated to reflux (63°C). Reflux was continued for 3 hours additional amounts of 2-bromo-3-(l-methylethoxy)-2-propenal (0.36 kg, 0.2 mol) was added to the vessel using 0.1 L tetrahydrofuran as rinse. After 4.0 hours reflux, additional 2-bromo-3-(l-methylethoxy)-2-propenal (0.18 kg, 0.1 mol) was added to the vessel using 0.1 L tetrahydrofuran as rinse. After 7.0 hours total reflux time, the reaction was cooled to 25°C and allowed to stand overnight with stirring. Water (3.6 L) was added to the vessel to dissolve any solids present and the solution was stirred 15 min. The solution was transferred to a 20 gallon, glass-lined fixed reactor. The original reactor was rinsed with 0.36 L of water which was also added to the 20 gallon vessel. This vessel was charged with ethyl acetate (21.5 L) and the suspension was stirred for 5 min and then allowed to settle. The dark aqueous
AP Ο Ο Ο 4 1 8
-8alkaline product layer was transferred to a carboy (20 L) then added to a gallon vessel. The 20 gallon vessel was charged with water (2.9 L) and the suspension was stirred 5 min then allowed to settle. The bottom aqueous layer was collected and added to the 10 gallon vessel while the top ethyl acetate layer was collected for disposal. The basic (pH 10.05) aqueous solution was acidified with 6 N hydrochloric acid (2.51 L) to pH 5.2 then was transferred to a 20 gallon vessel. The 10 gallon vessel was rinsed with methylene chloride (26 L) and added to the 20 gallon vessel. The contents of the vessel were stirred for 10 min and the layers allowed to separate. The lower organic layer was transferred to a carboy (20 L).
The 20 gallon vessel was charged with 4.3 L of methylene chloride and stirred for 5 min and then allowed to settle. After the phases separated, the bottom phase was collected in a carboy. The procedure was repeated once more with 4.3 L of methylene chloride. The combined methylene chloride extracts were added to a 10 gallon vessel and water was added (2.9 L). The suspension was stirred for 5 min then allowed to settle. The bottom organic layer was collected and placed in a portable 50 L glass tank. Under fast agitation, 0.67 kg of magnesium sulfate and 0.13 kg of activated charcoal were added and the suspension was filtered through a Buchner funnel containing Celite® under vacuum. The 10 gallon vessel was charged with the methylene chloride solution and the solvent was removed under vacuum until about 5 L remained. The reactor was then charged with 2-butanone (5.17 L) and solvent was removed under vacuum until the volume was 4-5 L. Ethyl acetate was added (13 L) and the suspension was stirred 16 hours. At this time, the solid was removed by filtration using a Buchner funnel under vacuum. The collected solid was rinsed with a mix of 2-butanone:ethyl acetate (10:90) and dried overnight under vacuum. The yield obtained was 1457 g (5.08 mol, 94.0% purity).
It is to be understood that the invention is not limited to the embodiment illustrated hereinabove and the right to the illustrated embodiment and all
Claims (9)
1. A process for the preparation of a compound of formula (I):
wherein:
Rl is hydrogen, phenyl, biphenyl, or naphthyl, with each group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, I,
10 Cj-Cgalkyl, nitro, A-CO2R6, tetrazol-5-yl, CpCgalkyl, SO2NHR6, NHSO2R6, SO3H, CONR6R6, CN, S02C1-C6alkoxy, hydroxy, SCpCgalkyl, NHSO2R6, PO(OR6)2, NR6R6, NR6COH, NR^OCpCgalkyl, NR6CON(R6)2, NR6COW, W, SO2W;
R^ is hydrogen, C2-C|galkyl, C3-Cigalkenyl, C3-CiQalkynyl, C315 C^cycloalkyl, or (CH2)o-8Phenyl unsubstituted or substituted by one to three substituents selected from Cj-C^alkyl, nitro, Cl, Br, F, I, hydroxy, Cj-Cgalkoxy, NR6r6, CO2R6, CN, CONR6R6 W, tetrazol-5-yl, NR6COCi-C6alkyl,
NR6COW, SCj-C^alkyl, SO2W, or SC^Cj-CGalkyl;
W is CqF2q+i, wherein q is 1-3;
20 A is -(CH2)n-, -CH=CH-, -O(CR4R5)m-, or -S(CR4R5)m-;
each R4, independently is hydrogen, Cj.Cgalkyl (unsubstituted or substituted by phenyl, biphenyl, naphthyl or C3-C6cycloalkyl), phenyl, biphenyl, or naphthyl (each of which is unsubstituted or substituted by one to three substituents selected from Cl, Br, I, F, Cj-Cgalkyl, (Ci-C5alkenyl)CH2,(Ci-C5alkynyl)CH2,
25 CpC^alkoxy, CpCgalkylthio, NO2, CF3, CO2R6, or OH), C3-C()Cycloalkyl, or phenyl(Cj-C2alkyl) unsubstituted or substituted by phenyl;
each R^ independently is hydrogen, Ci-Cgalkyl, or (CH2)nphenyl; each n independently is 0-4; and each m independently is 1-4;
30 or a pharmaceutically acceptable salt thereof, which comprises reacting a compound of formula (II):
BAD ORIGINAL
AP Ο Ο Ο 4 1 8
R —C—ΝΗ
I!
ΝΗ (Π) wherein:
Rl, and n are as defined above for formula (I), with a compound of formula (III):
wherein:
CHO (in)
X is Cl, Br, F, or I; and
Y is -OR3, -SR3 , or -N(R3)2, wherein R3 is Cj-Cgalkyl, under basic conditions and in solvent and, thereafter, optionally forming a pharmaceutically acceptable salt.
2. The process of claim 1 for preparing a compound wherein:
Ri is phenyl, biphenyl, or naphthyl, with each group being unsubstituted or substituted by one to three substituents selected from Cl, Br, F, CF3, Ci-Cgalkyl, nitro, CO2R6, -OCR^rScC^R^, tetrazol-5-yl, Cj-Cgalkoxy, hydroxy, CN, or SO2NHR6;
n is 1 or 2; and
R^ is C2-Cgalkyl.
3. The process of claim 2 for preparing a compound wherein:
Rl is phenyl or naphthyl substituted by CO2R6;
n is 1; and
R^ is C2Cgalkyl.
4. The process of claim 3 for preparing a compound which is 4-[(2-nbutyl-
5-formyl-lH-imidazol-l-yl)methyl]benzoic acid.
BAD ORIGINAL ft •115. The process of claim 3 for preparing a compound which is 4-[(2-nbutyl-5-formyl-lH-imidazol-l-yl)methyl]naphthoic acid.
6. The process of claims 4 and 5 in which the base is potassium 5 carbonate and the solvent is water and tetrahydrofuran.
7. The process of claim 3 for preparing a compound which is ethyl 4[(2-n-butyl-5-formyl-lH-imidazol-l-yl)methyl]benzoate.
10
8. The process of claim 3 for preparing a compound which is ethyl 4[(2-n-butyl-5-formyl-lH-imidazol-l-yl)methyl]naphthoate.
9. The process of claims 7 and 8 in which the base is triethylamine and the solvent in chloroform.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929220068A GB9220068D0 (en) | 1992-09-23 | 1992-09-23 | Process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9300565A0 AP9300565A0 (en) | 1993-10-31 |
| AP418A true AP418A (en) | 1995-10-24 |
Family
ID=10722348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1993/000565A AP418A (en) | 1992-09-23 | 1993-09-17 | A process for preparing useful intermediates in the synthesis of substituted imidazole compounds. |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP0662961B1 (en) |
| JP (1) | JPH08501307A (en) |
| KR (1) | KR100297505B1 (en) |
| CN (1) | CN1035613C (en) |
| AP (1) | AP418A (en) |
| AT (1) | ATE186531T1 (en) |
| AU (1) | AU676848B2 (en) |
| BG (1) | BG62328B1 (en) |
| BR (1) | BR9307201A (en) |
| CA (1) | CA2145181C (en) |
| CZ (1) | CZ282281B6 (en) |
| DE (1) | DE69327007T2 (en) |
| DK (1) | DK0662961T3 (en) |
| ES (1) | ES2137999T3 (en) |
| FI (1) | FI113170B (en) |
| GB (1) | GB9220068D0 (en) |
| GR (1) | GR3032015T3 (en) |
| HU (1) | HU224071B1 (en) |
| IL (1) | IL107047A (en) |
| MA (1) | MA22980A1 (en) |
| MX (1) | MX9305844A (en) |
| MY (1) | MY110202A (en) |
| NO (1) | NO304688B1 (en) |
| NZ (1) | NZ256223A (en) |
| OA (1) | OA10138A (en) |
| PH (1) | PH31154A (en) |
| PL (1) | PL173450B1 (en) |
| RO (1) | RO113146B1 (en) |
| RU (1) | RU2128174C1 (en) |
| SA (1) | SA93140423B1 (en) |
| SI (1) | SI9300494A (en) |
| SK (1) | SK281227B6 (en) |
| TW (1) | TW409124B (en) |
| UA (1) | UA41903C2 (en) |
| WO (1) | WO1994006776A1 (en) |
| ZA (1) | ZA936962B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565577A (en) * | 1992-09-23 | 1996-10-15 | Smithkline Beecham Corporation | Process for preparing 1-alkyaryl-2-alkyl-5-formylimidazole |
| GB9220068D0 (en) * | 1992-09-23 | 1992-11-04 | Smithkline Beecham Corp | Process |
| CN101287711A (en) | 2005-08-23 | 2008-10-15 | 宇部兴产株式会社 | Process for producing 1-substituted-5-acylimidazole compound |
| KR101472686B1 (en) * | 2013-07-09 | 2014-12-16 | 씨제이헬스케어 주식회사 | Method for preparation of benzimidazole derivatives |
| CN103435617B (en) * | 2013-08-22 | 2016-04-27 | 南京华安药业有限公司 | A kind of synthetic method of 6,7-dihydro-5H-pyrrolo-[1,2-a] imidazoles-2-formaldehyde |
| CN115894192A (en) * | 2022-12-05 | 2023-04-04 | 苏州诚和医药化学有限公司 | A kind of synthetic method, application and 2-bromomalonedial of 2-bromomalonic |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4482723A (en) * | 1983-04-11 | 1984-11-13 | Pfizer Inc. | Process for preparation of 4-acetyl-2-substituted-imidazoles |
| WO1994006776A1 (en) * | 1992-09-23 | 1994-03-31 | Smithkline Beecham Corporation | Process of synthesizing useful intermediates of substituted imidazole compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU250902A1 (en) * | 1968-06-24 | 1989-07-30 | Новокузнецкий научно-исследовательский химико-фармацевтический институт | Method of producing 4(5))-carbopropoxyimidazolyl-5(4)-amide of n-bis-(2-chloroethyl)-aminophenylacetic acid |
| JPS5671073A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| US4602093A (en) * | 1984-02-08 | 1986-07-22 | Merck & Co., Inc. | Novel substituted imidazoles, their preparation and use |
| DE3811621A1 (en) * | 1988-04-07 | 1989-10-26 | Merck Patent Gmbh | METHOD FOR PRODUCING 1H-IMIDAZOLE-5-CARBONIC ACID ESTERS OR NITRILES AND PYRROL-3,4-CARBONIC ACID ESTERS OR NITRILES AND USE OF THE PRODUCED COMPOUNDS FOR SYNTHESISING PILOCARPINE |
| US5234917A (en) * | 1989-12-29 | 1993-08-10 | Finkelstein Joseph A | Substituted 5-(alkyl)carboxamide imidazoles |
-
1992
- 1992-09-23 GB GB929220068A patent/GB9220068D0/en active Pending
-
1993
- 1993-09-07 CA CA002145181A patent/CA2145181C/en not_active Expired - Fee Related
- 1993-09-07 EP EP93921386A patent/EP0662961B1/en not_active Expired - Lifetime
- 1993-09-07 HU HU9500837A patent/HU224071B1/en not_active IP Right Cessation
- 1993-09-07 AU AU48496/93A patent/AU676848B2/en not_active Ceased
- 1993-09-07 BR BR9307201A patent/BR9307201A/en active Search and Examination
- 1993-09-07 RO RO95-00556A patent/RO113146B1/en unknown
- 1993-09-07 UA UA95048355A patent/UA41903C2/en unknown
- 1993-09-07 DE DE69327007T patent/DE69327007T2/en not_active Expired - Lifetime
- 1993-09-07 JP JP6508126A patent/JPH08501307A/en not_active Ceased
- 1993-09-07 WO PCT/US1993/008390 patent/WO1994006776A1/en not_active Ceased
- 1993-09-07 DK DK93921386T patent/DK0662961T3/en active
- 1993-09-07 CZ CZ95708A patent/CZ282281B6/en not_active IP Right Cessation
- 1993-09-07 AT AT93921386T patent/ATE186531T1/en active
- 1993-09-07 SK SK373-95A patent/SK281227B6/en not_active IP Right Cessation
- 1993-09-07 NZ NZ256223A patent/NZ256223A/en not_active IP Right Cessation
- 1993-09-07 ES ES93921386T patent/ES2137999T3/en not_active Expired - Lifetime
- 1993-09-07 RU RU95108600A patent/RU2128174C1/en not_active IP Right Cessation
- 1993-09-07 KR KR1019950701094A patent/KR100297505B1/en not_active Expired - Fee Related
- 1993-09-17 PH PH46894A patent/PH31154A/en unknown
- 1993-09-17 AP APAP/P/1993/000565A patent/AP418A/en active
- 1993-09-20 MY MYPI93001904A patent/MY110202A/en unknown
- 1993-09-20 IL IL107047A patent/IL107047A/en not_active IP Right Cessation
- 1993-09-21 ZA ZA936962A patent/ZA936962B/en unknown
- 1993-09-21 MA MA23293A patent/MA22980A1/en unknown
- 1993-09-22 MX MX9305844A patent/MX9305844A/en unknown
- 1993-09-23 SI SI9300494A patent/SI9300494A/en not_active IP Right Cessation
- 1993-09-23 CN CN93119602A patent/CN1035613C/en not_active Expired - Fee Related
- 1993-10-13 TW TW082108450A patent/TW409124B/en not_active IP Right Cessation
- 1993-12-18 SA SA93140423A patent/SA93140423B1/en unknown
-
1995
- 1995-03-20 OA OA60627A patent/OA10138A/en unknown
- 1995-03-21 PL PL93308173A patent/PL173450B1/en unknown
- 1995-03-22 FI FI951350A patent/FI113170B/en not_active IP Right Cessation
- 1995-03-22 NO NO951082A patent/NO304688B1/en not_active IP Right Cessation
- 1995-03-23 BG BG99520A patent/BG62328B1/en unknown
-
1999
- 1999-11-30 GR GR990403109T patent/GR3032015T3/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4482723A (en) * | 1983-04-11 | 1984-11-13 | Pfizer Inc. | Process for preparation of 4-acetyl-2-substituted-imidazoles |
| WO1994006776A1 (en) * | 1992-09-23 | 1994-03-31 | Smithkline Beecham Corporation | Process of synthesizing useful intermediates of substituted imidazole compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8350046B2 (en) | Method for manufacturing aryl carboxamides | |
| US7795471B2 (en) | Process for trans-4-amino-1-cyclohexanecarboxylic acid derivatives | |
| JP6688278B2 (en) | Method for producing 4-alkoxy-3-hydroxypicolinic acid | |
| RU2176241C2 (en) | Method of synthesis of derivatives of 3-amino-2-mercaptobenzoic acid (variants), derivatives of benzothiazole and method of their synthesis | |
| JP2530848B2 (en) | Process for producing O-substituted hydroxylamine | |
| AP418A (en) | A process for preparing useful intermediates in the synthesis of substituted imidazole compounds. | |
| US6372933B1 (en) | Process for preparing certain phenyl urea compounds | |
| US5565577A (en) | Process for preparing 1-alkyaryl-2-alkyl-5-formylimidazole | |
| AU737994B2 (en) | Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides | |
| HK1012357B (en) | Process of synthesizing useful intermediates of substituted imidazole compounds | |
| RU2154060C2 (en) | Method of synthesis of 5-substituted 2-chloropyridine | |
| JP7689742B2 (en) | 1,4-dihydro-4-oxoquinoline-2-carboxylates and methods for preparing 4-aminoquinoline compounds therefrom | |
| PL190946B1 (en) | Intermediate product for use in obtaining 2-imidazolyn-5-ones | |
| KR20040039430A (en) | Process for producing (2-nitrophenyl)acetonitrile derivative and intermediate therefor | |
| USRE40795E1 (en) | Process for producing 5-substituted oxazole compounds and 5-substituted imidazole compounds | |
| WO1997014688A1 (en) | A PROCESS FOR THE PREPARATION OF α-CHLOROMETHYLPHENYLACETIC ACID DERIVATIVES | |
| RU2270195C1 (en) | Method for preparing 5-amino-3-[n-acyl-n-alkylamino]-1-phenyl-1,2,4-triazoles and 5-amino-3-[n-sulfonyl-n-alkylamino]-1-phenyl-1,2,4-triazoles | |
| JP2001261604A (en) | Method for producing halogenopropyl ethers | |
| JPS63165354A (en) | Production of asymmetric cyanhydrin | |
| JP2007509092A (en) | Process for producing α- (3-arylthio) -acetophenones | |
| MXPA99009046A (en) | Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides | |
| JPH0948772A (en) | Process for producing aminothiazolyl acetic acid derivative |